Search results for " Liv"

showing 10 items of 2456 documents

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression.

2020

Nonalcoholic fatty liver disease (NAFLD), depression, and anxiety disorders are frequent diseases, and data on mutual influence are inconsistent. The aim of this study was to explore the incidence of depression and anxiety in a large primary care cohort in Germany and to study the impact of NAFLD over a 10‐year time frame. Patients with NAFLD diagnosed between 2010 and 2015 were matched to a cohort without NAFLD controlling for age, sex, physician, index year, and Charlson comorbidity index. The primary outcome of the study was the incidence of depression, anxiety, and first prescription of antidepressant drugs. We compared 19,871 patients with NAFLD to 19,871 matched controls. Within 10 ye…

medicine.medical_specialtyHepatologybusiness.industryIncidence (epidemiology)Hazard ratioConfoundingOriginal Articlesmedicine.diseaseInternal medicineNonalcoholic fatty liver diseaseCohortMedicineAnxietylcsh:Diseases of the digestive system. GastroenterologyOriginal Articlelcsh:RC799-869medicine.symptomRisk factorbusinessDepression (differential diagnoses)Hepatology communications
researchProduct

OC.03.2 THE PRESENCE OF WHITE MATTER LESIONS IS ASSOCIATED WITH THE HISTOLOGICAL SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

2016

medicine.medical_specialtyHepatologybusiness.industryInternal medicineFatty liverGastroenterologyMedicineNon alcoholicDiseasebusinessmedicine.diseaseGastroenterologyHyperintensityDigestive and Liver Disease
researchProduct

Early menopausal status is associated with the severity of liver fibrosis in Italian patients with non-alcoholic fatty liver disease

2014

medicine.medical_specialtyHepatologybusiness.industrySettore MED/12 - GASTROENTEROLOGIALiver fibrosisFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinebusinessDigestive and Liver Disease
researchProduct

Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors’ reply

2012

We thank Prof. Filik for his interest in our recent article. 2 He points to the fact that the interpretation of our results could be affected by lack of data on physical activity and diet. In response to this issue, we are aware that both physical activity and diet are able to affect not only anthropometric and metabolic parameters of visceral adiposity index (VAI) but also the severity of liver disease. Unfortunately, data on both physical activity and diet in our patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD) are not available, even if we are confident that their variations should not significantly affect our results. In fact, in our study, we evaluated histological…

medicine.medical_specialtyHepatologybusiness.industrySurrogate endpointFatty liverGastroenterologyNon alcoholicDiseaseAnthropometrymedicine.diseaseGastroenterologyLiver diseaseEndocrinologyInternal medicineMedicinePharmacology (medical)Liver damagebusinessMETABOLIC FEATURESAlimentary Pharmacology & Therapeutics
researchProduct

Treatment of chronic hepatitis C

1991

alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%. The patients who relapse are sensitive to retreatment with interferon-alpha. A better understanding of HCV replication and of the interferon action in this viral disease might help to further improve treatment schedules. Side effects of interferon were frequently mild and readily reversible after cessation of treatment. At present interferon treatment should not be recommended in asymptomatic patients or individ…

medicine.medical_specialtyHepatologybusiness.industryTreatment outcomeInterferon-alphaHepacivirusVirus ReplicationProgressive liver diseaseHepatitis CAsymptomaticGastroenterologyTreatment OutcomeViral replicationChronic hepatitisInterferonInternal medicineChronic DiseaseImmunologyHumansMedicineViral diseaseMillion Unitsmedicine.symptombusinessmedicine.drugJournal of Hepatology
researchProduct

Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease

2015

Excess hepatic storage of triglycerides is considered a benign condition, but nonalcoholic steatohepatitis (NASH) may progress to fibrosis and promote atherosclerosis. Carriers of the TM6SF2 E167K variant have fatty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs). As a result, they have lower circulating lipids and reduced risk of myocardial infarction. In this study, we aimed to assess whether TM6SF2 E167K affects liver damage and cardiovascular outcomes in subjects at risk of NASH. Liver damage was evaluated in 1,201 patients who underwent liver biopsy for suspected NASH; 427 were evaluated for carotid atherosclerosis. Cardiovascular outcomes were assessed …

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryFatty liverOdds ratioHepatologymedicine.diseaseLower riskEndocrinologyInternal medicineLiver biopsyCohortmedicineSteatosisNASH TM6SF2businessTM6SF2
researchProduct

Predictors of mortality and early detection strategies for hepatopulmonary syndrome in liver transplant patients☆

2016

Introduction: Hepatopulmonary syndrome (HPS) is a serious, progressive disease. Its pathophysiology resides in a hypoxic intrapulmonary shunt and severe clinical deterioration. Liver transplantation (LT) is the only effective treatment in appropriately selected patients. Objective: To acknowledge the importance of early diagnosis of HPS. Patients and methods: Observational, descriptive, retrospective trial including 8 patients with HPS that received LT between April 2006 and August 2014. The clinical data prior to transplantation and follow-up after the procedure were reviewed. A multivariate analysis (stepwise forward logistic regression analysis) was used to identify the variable that cou…

medicine.medical_specialtyHepatopulmonary syndromemedicine.medical_treatment030230 surgeryLiver transplantationCritical Care and Intensive Care MedicineGastroenterologyHypoxemiaAnestesiaBile canaliculus03 medical and health sciencesLiver disease0302 clinical medicineSíndrome hepatopulmonarInternal medicinemedicineHepatic insufficiencyAnesthesiaMortalityHepatopulmonary syndromeSurvival rateTransplante de hígadoHepatitisLiver transplantationmedicine.diagnostic_testbusiness.industryInsuficiencia hepáticaPolycystic liver diseasemedicine.diseaseSurgeryTransplantationmedicine.anatomical_structureAnesthesiology and Pain MedicineHepatocyteMortalidadPortal hypertension030211 gastroenterology & hepatologyTransplant patientmedicine.symptomLiver function testsbusinessProgressive diseaseColombian Journal of Anesthesiology
researchProduct

FRI0299 Prevalence of Vertebral Fractures in Osteoporotic HIP Fractured Patients: The Focus Study

2015

Background Osteoporosis is a multifactorial systemic skeletal disease, characterized by low bone mass and microarchitectural modifications of bone tissue, with a consequent increase in fragility fractures [1]. Vertebral fractures are the most prevalent osteoporotic fractures and osteoporotic hip fractures are the most serious complication of osteoporosis resulting in increased mortality and high socio-economic cost [2,3]. The coexistence of these two pathological conditions in elderly patients has been previously described, leading to even worse functional outcomes than each one alone [4]. Objectives To determine the prevalence of vertebral fractures in osteoporotic hip fractured women and …

medicine.medical_specialtyHip fractureActivities of daily livingbusiness.industryImmunologyOsteoporosismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyEpidemiologyPhysical therapyImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionComplicationbusinessConsensus developmentPathologicalmedia_commonAnnals of the Rheumatic Diseases
researchProduct

<i>PCSK9</i> rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD

2020

Background and Aims: The proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis, and its inhibition represents an effective therapy to lower LDL-C levels. In this study, we examined the impact of PCSK9 rs11591147 loss-of-function (LOF) variant on liver damage in a multicenter collection of patients at risk of nonalcoholic steatohepatitis (NASH), in clinical samples and experimental models. Methods: We considered 1,874 consecutive individuals at risk of NASH as determined by histology. The SNP rs11591147, encoding for the p.R46L variant of PCSK9, was genotyped by TaqMan assays. We also evaluated 1) PCSK9 mRNA hepatic expression in human liver, and 2…

medicine.medical_specialtyHuman liverbusiness.industryPCSK9Helsinki declarationFat accumulationInformed consentInternal medicineMedicinemedia_common.cataloged_instanceLiver damageEuropean unionbusinessPharmacogeneticsmedia_commonSSRN Electronic Journal
researchProduct

Estrogen receptors α (ERα), ERβ and their variants may be responsible for estrogen implication in human liver carcinogenesis and tumor progression

2009

medicine.medical_specialtyHuman liverbusiness.industrymedicine.drug_classEstrogen receptorGeneral MedicineToxicologymedicine.disease_causeEndocrinologyTumor progressionEstrogenInternal medicineMedicinebusinessCarcinogenesisEstrogen receptor alphaEstrogen receptor betaToxicology Letters
researchProduct